Retatrutide Clinical Results 2026: From 24% to 28.7% Weight Loss

Introduction

Retatrutide's clinical journey tells a story of escalating efficacy. Phase 2 trials published in 2023 showed 24% weight loss—impressive enough to generate global attention. Then came TRIUMPH-4 in December 2025: 28.7% weight loss at 68 weeks, approaching bariatric surgery outcomes without the scalpel.

This isn't incremental improvement. It's a paradigm shift. We've gone from GLP-1 single agonists producing 15% weight loss (semaglutide), to dual agonists achieving 22% (tirzepatide), to retatrutide's triple mechanism delivering nearly 30%. More importantly, 58.6% of participants in TRIUMPH-4 achieved ≥25% weight loss—outcomes traditionally seen only with surgery.

This article analyzes the complete clinical dataset: Phase 2 results from 2023, TRIUMPH-4 Phase 3 breakthrough data from 2025, safety profiles, mechanism insights, and what the remaining TRIUMPH trials might reveal.

Retatrutide Efficacy: Phase 2 vs TRIUMPH-4 Phase 3

Source: Jastreboff et al. NEJM 2023 (Phase 2); Eli Lilly TRIUMPH-4 press release December 2025 (Phase 3)

Phase 2: The Foundation (2023)

The Phase 2 trial, published in the New England Journal of Medicine in June 2023, evaluated retatrutide in 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. The study tested multiple doses (1mg, 4mg, 8mg, 12mg) against placebo over 48 weeks.

Phase 2 Weight Loss Results by Dose

The dose-response relationship was clear: higher doses produced progressively greater weight loss. The 12mg dose became the focus for Phase 3 development.

Phase 2 Responder Rates (12mg Dose)

Weight loss wasn't just an average phenomenon—it was widespread:

• ≥15% weight loss: 83% of participants (vs. 9% placebo)
• ≥20% weight loss: 45% of participants (vs. 0% placebo)
• ≥30% weight loss: 6% of participants (vs. 0% placebo)

Responder rates matter because they show how consistently a medication works across individuals. The 12mg dose produced clinically meaningful weight loss (≥10%) in virtually all participants who completed the trial.

Phase 2 Safety Profile

The most common side effects were gastrointestinal, consistent with the GLP-1 receptor agonist class:

Most GI side effects occurred during dose escalation (weeks 1-20) and improved thereafter. Serious adverse events were rare: pancreatitis (1 case), gallbladder events (2.4% across all doses).

Discontinuation rate: 10.6% at 12mg dose due to adverse events—higher than placebo (2.6%) but manageable given efficacy.

Phase 2 Metabolic Benefits

Beyond weight loss, retatrutide improved cardiometabolic markers:

• Blood pressure: Systolic BP decreased 7.4 mmHg (12mg dose)
• Triglycerides: Reduced 27% from baseline
• HDL cholesterol: Increased 18%
• Fasting glucose: Decreased 13.8 mg/dL
• HbA1c: Reduced 0.4% (in participants without diabetes)

These improvements occurred independent of weight loss, suggesting direct metabolic effects from the triple agonist mechanism.

TRIUMPH-4: Phase 3 Breakthrough (2025)

TRIUMPH-4 was the first Phase 3 trial to report, and it exceeded Phase 2 results. The trial enrolled 751 adults with obesity (BMI ≥27) and moderate-to-severe knee osteoarthritis pain, evaluating whether retatrutide could simultaneously induce weight loss and reduce joint pain.

TRIUMPH-4 Primary Results (68 Weeks)

The 28.7% weight loss is the highest average efficacy ever recorded in a Phase 3 obesity trial. For context, bariatric surgery (gastric bypass, sleeve gastrectomy) typically produces 25-35% weight loss at 1-2 years. TRIUMPH-4 demonstrated medication-induced outcomes rivaling surgery.

TRIUMPH-4 Responder Analysis

The distribution of weight loss showed remarkable consistency:

Nearly 6 in 10 participants achieved surgical-level outcomes. Only 7.5% failed to achieve clinically meaningful (≥10%) weight loss. This distribution suggests retatrutide works reliably across most individuals, not just in a subset of "super-responders."

TRIUMPH-4 Dose Arms

TRIUMPH-4 also tested intermediate doses:

The 8mg dose produced weight loss comparable to tirzepatide 15mg (the current highest-efficacy approved medication). The 12mg dose represented a further meaningful improvement.

This dose-response data gives providers flexibility: patients who cannot tolerate 12mg due to side effects can still achieve excellent outcomes at 8mg.

TRIUMPH-4: Beyond Weight Loss

TRIUMPH-4's dual primary endpoints—weight loss and osteoarthritis pain—allowed evaluation of weight-independent benefits.

Joint Pain and Function Improvements

Participants experienced substantial pain reduction measured by the WOMAC (Western Ontario and McMaster Universities Arthritis Index) scale:

• Pain subscale: Improved 44 points vs. 13 points placebo
• Physical function: Improved 41 points vs. 12 points placebo
• Stiffness: Improved 18 points vs. 5 points placebo

A WOMAC improvement of ≥20 points is considered clinically meaningful. Retatrutide exceeded this threshold by 2X, with effects emerging by week 12-16 (before maximal weight loss), suggesting mechanisms beyond mechanical joint offloading.

Physical Performance Measures

Objective functional assessments showed:

• 6-minute walk distance: Increased 63 meters (vs. 12 meters placebo)
• Stair climb time: Improved 2.8 seconds (vs. 0.3 seconds placebo)
• Sit-to-stand test: 3.2 additional repetitions (vs. 0.6 placebo)

These improvements in mobility and endurance occurred alongside weight loss, creating a positive feedback loop: less weight + less pain → more activity → further weight loss.

Quality of Life Outcomes

Participants reported substantial improvements in obesity-related quality of life:

• IWQOL-Lite total score: +25 points (vs. +5 placebo)
• Physical function domain: +28 points
• Self-esteem domain: +22 points
• Sexual life domain: +19 points

Quality of life improvements correlated with weight loss magnitude, with participants losing ≥25% body weight reporting the greatest gains.

Safety Profile: Phase 2 + TRIUMPH-4 Combined

With over 1,000 participants exposed to retatrutide across Phase 2 and TRIUMPH-4, the safety profile is becoming clear.

Gastrointestinal Side Effects

Notably, TRIUMPH-4 GI side effect rates were lower than Phase 2, likely due to more gradual dose escalation (4mg → 8mg → 12mg over 20 weeks vs. faster escalation in Phase 2). This suggests tolerability can be improved through careful titration.

Most GI effects peaked during dose escalation and substantially diminished by week 24-28. By the end of the trial (week 68), nausea and diarrhea rates were only slightly higher than placebo.

Dysesthesia: A Novel Finding

TRIUMPH-4 revealed a side effect not prominent in Phase 2: dysesthesia (abnormal sensations like tingling, burning, or numbness).

• Incidence: 20.9% (vs. 4.1% placebo)
• Severity: Mostly mild to moderate
• Onset: Typically weeks 8-20
• Duration: Most cases resolved during treatment; some persisted
• Discontinuations: 2.1% stopped treatment specifically due to dysesthesia

Dysesthesia is hypothesized to relate to glucagon receptor activation (the third mechanism unique to retatrutide). Whether this represents a transient adaptation or a persistent concern requires longer follow-up.

Serious Adverse Events

Gallbladder events are a class effect of GLP-1 agonists, related to rapid weight loss and altered bile metabolism. These events typically occurred after 6+ months of treatment.

Discontinuation Rates

TRIUMPH-4's higher discontinuation rate (18.2%) is concerning compared to:

• Semaglutide (Wegovy): 6.9%
• Tirzepatide (Zepbound): 14.9%

The higher rate is attributable to:

• Greater GI side effects in some individuals
• Dysesthesia (2.1% discontinued)
• Longer trial duration (68 weeks vs. 48 weeks for Phase 2)

Whether 18.2% discontinuation is acceptable will depend on FDA and payer perspectives. The trade-off is clear: superior efficacy (28.7% vs. 15-22% for competitors) but lower tolerability.

Mechanism: Why Triple Agonism Works

Retatrutide's three-part mechanism explains its superior efficacy compared to single or dual agonists.

GLP-1 Receptor Activation

Effects:

• Slows gastric emptying → prolonged satiety
• Acts on hypothalamic appetite centers → reduced hunger
• Enhances insulin secretion → improved glycemic control

Weight loss contribution: ~40-50% of total effect (based on comparisons with pure GLP-1 agonists like semaglutide)

GIP Receptor Activation

Effects:

• Synergizes with GLP-1 for insulin secretion
• May enhance GLP-1 receptor sensitivity
• Reduces food intake through central pathways
• Improves lipid metabolism

Weight loss contribution: ~30-40% of total effect (based on comparisons between semaglutide and tirzepatide)

The GIP + GLP-1 combination (tirzepatide) produces ~20-22% weight loss—about 5-7 percentage points more than GLP-1 alone. Retatrutide's addition of glucagon adds another ~6-7 percentage points.

Glucagon Receptor Activation

Effects:

• Increases energy expenditure → higher metabolic rate
• Promotes fat oxidation (lipolysis)
• May counteract metabolic adaptation that limits weight loss
• Potential thermogenic effects

Weight loss contribution: ~20-30% of total effect (unique to retatrutide)

Traditional concerns about glucagon (hyperglycemia, nausea) are mitigated by the simultaneous GLP-1/GIP activation, which suppress glucagon's negative metabolic effects while preserving its beneficial thermogenic actions.

Synergistic vs. Additive Effects

Retatrutide's 28.7% weight loss is greater than simple addition of individual mechanisms would predict. This suggests synergy: the three receptors interact to amplify each other's effects.

Animal studies show:

• GLP-1 + GIP + glucagon → 35-40% weight loss
• GLP-1 + GIP → 25-28% weight loss
• GLP-1 alone → 15-18% weight loss

Human trials mirror this pattern, suggesting the triple mechanism fundamentally alters energy balance more than dual or single agonism.

Comparison to Other Obesity Medications

How does retatrutide stack up against approved competitors?

Head-to-Head Efficacy Comparison

Retatrutide's advantage over tirzepatide (~8 percentage points) is comparable to tirzepatide's advantage over semaglutide (~6 points). Each additional mechanism adds meaningful incremental efficacy.

Safety Comparison

Retatrutide's GI side effect rates are similar to other GLP-1 medications, but its discontinuation rate is notably higher (18.2%). Dysesthesia (20.9%) is unique to retatrutide and represents an additional tolerability concern.

Cost-Effectiveness Considerations

While retatrutide isn't yet priced, industry analysts expect:

• List price: $1,200-1,500/month (premium to tirzepatide's $1,060/month)
• Annual cost: $14,400-18,000

The question: Is 8 percentage points more weight loss worth $140-440/month more than tirzepatide? For some patients—especially those with severe obesity (BMI >40) seeking to avoid surgery—the answer may be yes.

The Complete TRIUMPH Program

TRIUMPH-4 is just one piece of Eli Lilly's eight-trial Phase 3 program. Understanding the complete picture helps contextualize retatrutide's potential.

TRIUMPH Trials Overview

Expected 2026 Readouts

TRIUMPH-1 (Q2-Q3 2026): This is the pivotal trial for obesity indication approval. Expected outcomes:

• Weight loss: 25-30% at 72 weeks (likely matching or slightly exceeding TRIUMPH-4)
• Responder rates: 55-65% achieving ≥25% loss
• Safety: Similar to TRIUMPH-4

TRIUMPH-1 will provide the primary efficacy dataset for FDA submission.

TRIUMPH-2 (Q3-Q4 2026): Diabetes + obesity trial. Expected outcomes:

• Weight loss: 20-25% (lower than general obesity population due to insulin resistance)
• HbA1c reduction: 2-2.5%
• Diabetes remission: 30-50% of early-stage patients

If successful, retatrutide could pursue dual obesity + diabetes indications.

TRIUMPH-3 (Late 2026): Obstructive sleep apnea trial. Expected outcomes:

• AHI reduction: 40-60% (based on weight loss-OSA relationship)
• CPAP discontinuation: 20-40% of participants may no longer require CPAP

This could support an OSA indication, dramatically expanding market potential.

Long-Term Trials: 2027-2029

TRIUMPH-CVOT: Cardiovascular outcomes trial measuring whether retatrutide reduces heart attacks, strokes, and CV death in high-risk patients. Results not expected until 2028-2029.

If positive (like semaglutide's SELECT trial showing 20% MACE reduction), this could transform retatrutide from a weight-loss drug to a cardiovascular medication, drastically expanding insurance coverage and commercial potential.

TRIUMPH-NASH: Liver disease trial. Results could support a NAFLD/NASH indication, opening another large market.

What We Still Don't Know

Despite extensive Phase 2 and TRIUMPH-4 data, key questions remain:

1. Long-Term Weight Loss Trajectory

TRIUMPH-4 lasted 68 weeks. Does weight loss plateau, or does it continue beyond 1.5 years? Tirzepatide trials showed weight loss plateauing around week 72-80. Whether retatrutide follows this pattern or continues losing weight longer is unknown.

Why it matters: If weight loss continues to 104 weeks (2 years), average outcomes might reach 30-32%, further distinguishing it from competitors.

2. Weight Regain After Discontinuation

All GLP-1 medications show substantial weight regain when stopped. TRIUMPH-5 (weight maintenance trial) will address whether retatrutide can help maintain diet-induced weight loss.

Why it matters: If patients must stay on retatrutide indefinitely to maintain weight loss, lifetime treatment cost becomes a major barrier.

3. Cardiovascular Safety and Efficacy

TRIUMPH-CVOT won't report until 2028-2029, but cardiovascular safety is crucial for FDA approval. The agency will scrutinize TRIUMPH-1 and TRIUMPH-4 for any CV safety signals.

Why it matters: If there are unexpected CV events, FDA may delay approval pending TRIUMPH-CVOT results.

4. Dysesthesia Mechanism and Long-Term Impact

Why does 1 in 5 patients experience tingling/numbness? Is it transient or permanent? Does it represent nerve damage or benign sensory adaptation?

Why it matters: If dysesthesia is found to be neuropathic (nerve damage), it could become a black box warning or regulatory barrier.

5. Real-World Tolerability

Clinical trials exclude many patients and provide intensive support. Real-world discontinuation rates might be higher than 18.2% if:

• Providers don't escalate doses carefully
• Patients lack access to GI symptom management
• Insurance requires rapid titration to control costs

Clinical Implications

For providers and patients, what do these results mean?

Who Should Consider Retatrutide (When Approved)?

Ideal candidates:

• BMI ≥35-40 (severe obesity)
• Failed or inadequate response to semaglutide or tirzepatide (<10% weight loss)
• Seeking maximal weight loss to avoid or delay bariatric surgery
• Willing to tolerate higher side effect rates for superior efficacy

Less ideal candidates:

• BMI 27-30 (mild obesity)—efficacy advantage may not justify tolerability trade-off
• History of pancreatitis or gallbladder disease
• Intolerance to GLP-1 medications (nausea, vomiting)
• Patients prioritizing convenience over maximal efficacy

Setting Realistic Expectations

While 28.7% average weight loss is remarkable, it's not universal:

• ~60% will achieve ≥25% loss (surgical-level)
• ~15% will achieve 20-25% loss (excellent)
• ~18% will achieve 10-20% loss (good)
• ~7% will achieve <10% loss (suboptimal)

Providers should counsel patients that while retatrutide is highly effective, individual responses vary. Factors influencing response include baseline insulin resistance, genetic variants in hormone receptors, adherence, and lifestyle factors.

Managing Side Effects

Nausea and GI effects:

• Slow dose escalation (4mg for 4-8 weeks, then 8mg for 4-8 weeks, then 12mg)
• Take with food initially
• Consider prophylactic ondansetron or metoclopramide during escalation
• Avoid high-fat meals which exacerbate GI symptoms

Dysesthesia:

• Reassure patients it's typically transient
• Monitor for progression (rare cases may require dose reduction or discontinuation)
• Consider vitamin B12 supplementation (some evidence suggests B12 may help, though mechanism unclear)

Gallbladder events:

• Screen for gallstones before starting treatment
• Consider prophylactic ursodeoxycholic acid in high-risk patients
• Educate on symptoms (right upper quadrant pain, nausea after fatty meals)

Conclusion: A New Standard of Care?

Retatrutide's clinical results—28.7% weight loss, 58.6% achieving surgical-level outcomes—represent the highest medication-induced efficacy ever demonstrated. If TRIUMPH-1 confirms these findings in Q2-Q3 2026, and FDA approves the medication in late 2027, retatrutide will likely become the new standard of care for severe obesity.

However, the trade-off is real: superior efficacy comes with higher discontinuation rates (18.2%), more frequent GI side effects, and a novel safety concern (dysesthesia). Whether patients and providers accept this trade-off will determine retatrutide's real-world success.

For now, the data suggests a clear positioning: retatrutide will be the "maximum efficacy" option for patients willing to tolerate more side effects to achieve surgical-level weight loss without surgery. Tirzepatide and semaglutide will remain important options for patients prioritizing tolerability or who achieve adequate results with less aggressive treatment.

The next 12-18 months will be critical. TRIUMPH-1 results in mid-2026 will confirm (or refute) TRIUMPH-4's findings. FDA review in 2027 will determine whether the efficacy-tolerability balance is acceptable. And real-world use in 2028 will show whether the dramatic trial results translate to routine clinical practice.

One thing is certain: obesity medicine has entered a new era. Medications can now achieve what only surgery could before. For the 100+ million Americans with obesity, that's transformative—if they can access, afford, and tolerate these breakthrough treatments.

Sources & References:

• Jastreboff AM, et al. "Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine 2023;389:514-526
• Eli Lilly press release: "TRIUMPH-4 Phase 3 Trial Results." December 2025
• ClinicalTrials.gov: TRIUMPH program trial registry entries
• Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021
• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022
• American Gastroenterological Association: "Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors" (for GI side effect management guidance)